Amplia Therapeutics is a biotech company specializing in developing targeted therapies for cancer and fibrosis, with a particular focus on drug candidates that inhibit Focal Adhesion Kinase (FAK). Its leading products are aimed at treating conditions like pancreatic cancer and idiopathic pulmonary fibrosis, both of which have limited treatment options and represent significant market potential if successful.
Amplia Therapeutics Limited (ATX) share price forecast requires a look at its strategic positioning in the biotech sector, potential advancements in its clinical programs, and the broader pharmaceutical market trends.
Achieving regulatory milestones (FDA, EMA, or TGA approval) is a significant factor for biotech companies. For Amplia, moving from clinical trials to regulatory approval for its drugs would be transformative, opening up commercialization opportunities that could positively impact its long-term stock valuation.
Amplia’s financial stability, partnership deals, and licensing agreements will impact its long-term outlook. Partnerships with larger pharmaceutical companies for research funding, clinical trials, and commercialization can provide necessary resources and reduce risks. Additionally, licensing agreements for successful therapies could lead to revenue generation.
With a focus on cancer and fibrosis, Amplia operates in high-demand markets. If its treatments prove effective, Amplia could capture a segment of these markets, which are expected to grow due to an ageing population and increasing incidence of chronic diseases.
Amplia Therapeutics’ stock has the potential for long-term growth, especially if it achieves significant clinical and regulatory milestones. However, the investment comes with substantial risks inherent to biotech development. Investors interested in Amplia should closely monitor clinical updates, regulatory progress, and financial health as these factors will greatly influence its stock trajectory over the coming decades.
Amplia Therapeutics Limited (ATX) share price forecast: History
Amplia Therapeutics Limited (ASX: ATX) is a clinical-stage biotech company that has demonstrated both growth potential and investment risks typical of the high-risk, high-reward biotech sector.
Since its inception, Amplia’s stock has seen fluctuations influenced by developments in its drug pipeline, particularly the progress of its Focal Adhesion Kinase (FAK) inhibitors targeting cancer and fibrosis. The company’s share price performance generally reacts to news about clinical trial advancements and funding announcements, reflecting investor sentiment on its progress toward regulatory approval and eventual commercialization.
Amplia’s stock price trajectory will be heavily influenced by the progress and results of its clinical trials, especially for its lead compounds AMP945 and AMP886. Successful trial phases and positive results could boost investor confidence and lead to substantial stock price increases, while setbacks may have the opposite effect.
| Date | High (AUD) | Low (AUD) |
|---|---|---|
| January 2020 | 0.0732 | 0.0732 |
| January 2021 | 0.2771 | 0.2375 |
| January 2022 | 0.1850 | 0.1650 |
| January 2023 | 0.0890 | 0.0850 |
| January 2024 | 0.0820 | 0.0800 |
| October 2024 | 0.1350 | 0.1150 |
Amplia Therapeutics Limited (ATX) share price forecast: 2025-55
Amplia Therapeutics Limited (ATX) share price forecast can achieve new heights with their hike this can help the companies to establish trust in the share market story.
| Year | open | high |
| 2025 | 0.0150 | 0.0170 |
| 2026 | 0.0172 | 0.0176 |
| 2027 | 0.0178 | 0.0183 |
| 2028 | 0.0183 | 0.0188 |
| 2029 | 0.0192 | 0.0196 |
| 2030 | 0.0195 | 0.1060 |
| 2035 | 0.1130 | 0.1170 |
| 2040 | 0.1187 | 0.1235 |
| 2045 | 0.1276 | 0.1313 |
| 2055 | 0.2312 | 0.2356 |
This period is crucial as Amplia may complete its clinical trials and, if successful, could achieve initial regulatory approvals. Positive outcomes during this phase could attract significant investor interest, leading to higher stock prices.
Amplia Therapeutics Limited (ATX) share price forecast:2024
The price prediction for Amplia Therapeutics Limited (ATX) for the year 2024 can vary from 0.0630AUD- 0.1600AUD
| Date | High (AUD) | Low (AUD) |
| January 2024 | 0.0800 | 0.0800 |
| February 2024 | 0.0810 | 0.0800 |
| March 2024 | 0.0750 | 0.0750 |
| April 2024 | 0.0800 | 0.0750 |
| May 2024 | 0.0620 | 0.0620 |
| June 2024 | 0.0720 | 0.0700 |
| July 2024 | 0.0620 | 0.0620 |
| August 2024 | 0.1000 | 0.0950 |
| September 2024 | 0.1050 | 0.0910 |
| October 2024 | 0.1600 | 0.1500 |
| November 2024 | 0.1350 | 0.1150 |
| December 2024 | 0.0170 | 0.0150 |
Amplia Therapeutics Limited (ATX) share price forecast : 2025
The price prediction for the Amplia Therapeutics Limited (ATX) for the year 2025 can vary from 0.0150AUD- 0.0170AUD
| Date | High (AUD) | Low (AUD) |
| FY2025 | 0.0170 | 0.0150 |
Amplia Therapeutics Limited (ATX) share price forecast:2026
The price prediction for the Amplia Therapeutics Limited (ATX) for the year 2026 can vary from 0.0172AUD- 0.0176AUD
| Year | Open (AUD) | High (AUD) |
| FY2026 | 0.0172 | 0.0176 |
Amplia Therapeutics Limited (ATX) share price forecast 2030
The price prediction for the Amplia Therapeutics Limited (ATX) for the year 2030 can vary from 0.0195AUD- 0.1060AUD
| Year | Open (AUD) | High (AUD) |
| FY2030 | 0.0195 | 0.1060 |
Amplia Therapeutics Limited (ATX) share price forecast : 2035
The price prediction for the Amplia Therapeutics Limited (ATX) for the year 2035 can vary from 0.1130AUD- 0.1170AUD
| Date | High (AUD) | Low (AUD) |
| FY2035 | 0.1170 | 0.1130 |
Amplia Therapeutics Limited (ATX) share price forecast: 2040
The price prediction for the Amplia Therapeutics Limited (ATX) for the year 2040 can vary from 0.1187AUD- 0.1235AUD
| Year | Open (AUD) | High (AUD) |
| FY2040 | 0.1187 | 0.1235 |
Amplia Therapeutics Limited (ATX) share price forecast: 2045
The price prediction for the Amplia Therapeutics Limited (ATX) for the year 2045 can vary from 0.1276AUD-0.1313AUD
| Date | High (AUD) | Low (AUD) |
| FY2045 | 0.1313 | 0.1276 |
Amplia Therapeutics Limited (ATX) share price forecast: 2050
The price prediction for the Amplia Therapeutics Limited (ATX) for the year 2050 can vary from 0.1269AUD-0.1296AUD
| Year | Open (AUD) | High (AUD) |
| FY2050 | 0.1269 | 0.1296 |
Amplia Therapeutics Limited (ATX) share price forecast: 2055
In the long term, Amplia’s stock performance will hinge on its success in advancing its lead drug candidates through clinical trials and achieving regulatory approval. Success could drive substantial stock appreciation as it moves toward revenue generation, while setbacks would likely hinder growth prospects. When considering a position in the company, investors should carefully weigh these factors and maintain a close watch on Amplia’s progress, funding initiatives, and broader biotech market trends.
| Date | High (AUD) | Low (AUD) |
| FY2055 | 0.2356 | 0.2312 |
check this: Pancontinental Energy NL (PCL) share price forecast from 2025 to 2055 (Detailed Analysis)
Amplia Therapeutics Limited (ATX) share price forecast: Valuation measures
| Market Cap | 37.10M |
| Enterprise Value | 35.30M |
| Trailing P/E | – |
| Forward P/E | – |
| PEG ratio (5 yr expected) | – |
| Price/Sales | – |
| Price/Book | 3.25 |
| Enterprise Value/Revenue | – |
| Enterprise Value/ EBITDA | – |
Amplia Therapeutics Limited (ATX) share price forecast: Financial Highlights
Profitability And income statement
| Profit Margin | -101.14% |
| Return on Assets (ttm) | -17.04% |
| Return on equity (ttm) | -33.05% |
| Revenue (ttm) | 4.45M |
| Net income Avi to common (ttm) | -4.5M |
| Diluted EPS (ttm) | -0.0200 |
Amplia Therapeutics Limited (ATX) share price forecast: Balance Sheet and Cash Flow
| Total cash (mrq) | 3.39M |
| Total Debt/Equity (mrq) | 13.90% |
| Levered Free cash Flow (ttm) | -3.59M |
Amplia Therapeutics Limited (ATX) share price forecast: Investor’s advice
Broader economic factors can affect the biotech sector. During economic downturns, investors often turn away from speculative, high-risk investments, which can impact Amplia’s stock and its access to funding. Clinical trials carry a high risk of failure, and only a fraction of drug candidates make it to market. Delays in trial phases or failure to show efficacy can significantly hurt stock performance. Additionally, even successful trials require navigating complex regulatory approvals, which can be uncertain and time-consuming.
Amplia faces competition from both established pharmaceutical companies and other biotech firms working on similar cancer and fibrosis treatments. The development of more effective or cost-efficient treatments by competitors could reduce Amplia’s market potential and impact its stock growth.
Amplia’s financial position is critical to its ability to continue operations and advance its clinical trials. Without revenue from commercialised products, the company’s reliance on external financing could expose it to cash flow risk. In a challenging capital environment, raising additional funds could lead to further dilution of shareholder value.
Conclusion
Amplia Therapeutics Limited (ASX: ATX) is positioned within the high-growth biotech sector, focusing on innovative cancer and fibrosis treatments through its Focal Adhesion Kinase (FAK) inhibitors. The company’s long-term stock performance will depend on successful clinical trials, regulatory approvals, and the commercialization of its pipeline products. However, Amplia is subject to significant risks typical in biotech, including trial failures, funding challenges, and competition. The stock may appeal to high-risk-tolerant investors with a long-term outlook due to its potential for breakthrough advancements in medical treatment.
Amplia Therapeutics Limited (ATX) share price forecast: FAQS
What type of company is Amplia Therapeutics Limited (ATX)?
Amplia focuses on developing FAK inhibitors that target diseases like cancer and fibrosis. Its lead candidates are designed to interfere with cellular pathways to improve treatment outcomes in these conditions.
What are the main risks associated with investing in Amplia Therapeutics Limited (ATX) share price?
Key risks include clinical trial failure, competition from other biotech firms, financial dependency on external funding, and sector sensitivity to economic downturns. These factors create high volatility and uncertainty in the stock.
How does the biotech market environment affect Amplia Therapeutics Limited (ATX) share performance?
The biotech market can be volatile, influenced by investor sentiment, breakthroughs in medical science, regulatory shifts, and broader economic conditions. Amplia’s stock is subject to these external factors, which can result in significant short-term volatility.
Disclaimer
This article only contains information for educational and informational purposes. It should not be interpreted as investment or financial advice. There are risks associated with investing in the stock market, and the value of investments can fluctuate. Before making any investment decisions, readers should conduct their research or speak with a financial advisor. Any losses or damages incurred as a result of using the information provided are beyond the control of the article’s author and publisher. Performance in the past does not guarantee success in the future.
Hello, I’m Bianca Paterson, a seasoned financial professional based in Sydney, Australia. With over 25 years of experience at ASX and an extensive background in share price predictions and market factors, I’ve cultivated a deep understanding of the dynamics that drive the financial markets.
I embarked on my journey with the ASX Graduate Program and have since dedicated my career to navigating the complexities of the share market. My insights are shaped by decades of hands-on experience, making me well-versed in the subtleties of market trends and investment strategies.
Through my blog, I aim to share my knowledge and offer valuable perspectives to fellow investors and market enthusiasts. Whether you’re a seasoned trader or just starting out, I hope my analysis and commentary will help you make informed decisions and better understand the ever-evolving landscape of the Australian stock market.